Ortataxel

Star0

DB11669InvestigationalSmall molecule

Ortataxel has been used in trials studying the treatment of Lymphoma, Lung Cancer, Glioblastoma, and Kidney Cancer.

Formula / weight: C₄₄H₅₇NO₁₇ · 871.93 g/mol (avg)
Code names: BAY 59-8862 · IDN-5109 · SB-T 101131

Resolves to

Compound

UNII8H61Y4E29NCAS186348-23-2ChEMBLCHEMBL382300PubChem6918412

Structure

InChIKeyBWKDAMBGCPRVPI-ZQRPHVBESA-NSMILES

CC(C)C[C@H](NC(=O)OC(C)(C)C)[C@@H](O)C(=O)O[C@H]1[C@@H]2OC(=O)O[C@@]22[C@@H](OC(=O)C3=CC=CC=C3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C(=C1C)C2(C)C)OC(C)=O

Targets

P01375TNF

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

7Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Ortataxel, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account